ATARA BIOTHERAPEUTICS, INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent of 0.00% for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-01.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2021-03-01
- ATARA BIOTHERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2020 was 0.00%.
- ATARA BIOTHERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2019 was 0.00%, a 100.00% decline from fiscal 2018.
- ATARA BIOTHERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2018 was 7.80%.
- ATARA BIOTHERAPEUTICS, INC. effective income tax rate reconciliation, nondeductible expense, research and development, percent for fiscal 2017 was 0.00%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent 12 month |
|---|---|
| 2020-12-31 | 0.00% 10-K · filed 2021-03-01 |
| 2019-12-31 | 0.00% 10-K · filed 2021-03-01 |
| 2018-12-31 | 7.80% 10-K · filed 2021-03-01 |
| 2017-12-31 | 0.00% 10-K · filed 2020-02-27 |
| 2016-12-31 | 0.00% 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |